

Appl. No. 10/771,259

14. (Currently Amended) The pharmaceutical composition according to claim 13 comprising 1-5% (w/w) acyclovir.

15. (Currently Amended) The pharmaceutical composition according to claim 14 comprising 0.25-1% (w/w) hydrocortisone.

16. (Currently Amended) A cream, lotion, gel, ointment, plaster, stick or pen containing a pharmaceutical composition according to any one of claims ~~1-15~~ 4-15.

17. Cancelled

18. (Currently Amended) A method for ~~the prophylaxis and/or treatment of treating~~ herpes virus infections of the skin or mucous membranes in mammals having or identified as being at risk of developing said infections comprising topically administering thereto, in combination or in sequence, of a therapeutically synergistic dose of a topically acceptable antiviral substance selected from the group consisting of acyclovir, cidofovir, desciclovir, famciclovir, ganciclovir, lobucavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and H2G or an ester, salt or solvate thereof and an anti-inflammatory glucocorticoid selected from the group consisting of alclometasone, amcinonide, beclomethasone, budesonide, ciclesonide, clobetasone, clocortolone, cloprednol, cortison, desonide, desoximethasone, dexamethasone, diflorosane, difluocortolone, difluprednate, fludrocortisone, fludroxycortid, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluprednidene, fluticasone, halcinonide, halobetasol, halometasone, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednicarbate, prednisone, prednylidene, rofleponide, tipredane and triamcinolone and their esters, salts and solvates in a pharmaceutically acceptable carrier.

19. Cancelled